vs
Real Brokerage Inc（REAX）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Real Brokerage Inc的1.4倍（$772.1M vs $568.5M），Revvity净利率更高（12.7% vs -0.1%，领先12.8%），Real Brokerage Inc同比增速更快（52.6% vs 5.9%），Revvity自由现金流更多（$161.8M vs $8.4M）
该企业是美国房产服务企业，主营房产经纪业务运营与品牌特许经营，业务覆盖房产中介、 relocation服务、产权服务、保险及结算服务，旗下拥有Better Homes and Gardens Real Estate、21世纪不动产、Coldwell Banker、Corcoran Group、ERA房地产以及苏富比国际地产等多个知名品牌，2026年被Compass, Inc.收购。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
REAX vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.4倍
$568.5M
营收增速更快
REAX
高出46.8%
5.9%
净利率更高
RVTY
高出12.8%
-0.1%
自由现金流更多
RVTY
多$153.4M
$8.4M
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $568.5M | $772.1M |
| 净利润 | $-447.0K | $98.4M |
| 毛利率 | 7.9% | — |
| 营业利润率 | -0.1% | 14.5% |
| 净利率 | -0.1% | 12.7% |
| 营收同比 | 52.6% | 5.9% |
| 净利润同比 | 82.7% | 3.9% |
| 每股收益（稀释后） | $0.00 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收REAXRVTY
| Q4 25 | — | $772.1M | ||
| Q3 25 | $568.5M | $698.9M | ||
| Q2 25 | $540.7M | $720.3M | ||
| Q1 25 | $354.0M | $664.8M | ||
| Q4 24 | — | $729.4M | ||
| Q3 24 | $372.5M | $684.0M | ||
| Q2 24 | — | $691.7M | ||
| Q1 24 | $200.7M | $649.9M |
净利润REAXRVTY
| Q4 25 | — | $98.4M | ||
| Q3 25 | $-447.0K | $46.7M | ||
| Q2 25 | $1.5M | $53.9M | ||
| Q1 25 | $-5.0M | $42.2M | ||
| Q4 24 | — | $94.6M | ||
| Q3 24 | $-2.6M | $94.4M | ||
| Q2 24 | — | $55.4M | ||
| Q1 24 | $-16.1M | $26.0M |
毛利率REAXRVTY
| Q4 25 | — | — | ||
| Q3 25 | 7.9% | 53.6% | ||
| Q2 25 | 8.9% | 54.5% | ||
| Q1 25 | 9.6% | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | 8.6% | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | 10.3% | 54.6% |
营业利润率REAXRVTY
| Q4 25 | — | 14.5% | ||
| Q3 25 | -0.1% | 11.7% | ||
| Q2 25 | 0.3% | 12.6% | ||
| Q1 25 | -1.5% | 10.9% | ||
| Q4 24 | — | 16.3% | ||
| Q3 24 | -0.7% | 14.3% | ||
| Q2 24 | — | 12.4% | ||
| Q1 24 | -7.8% | 6.8% |
净利率REAXRVTY
| Q4 25 | — | 12.7% | ||
| Q3 25 | -0.1% | 6.7% | ||
| Q2 25 | 0.3% | 7.5% | ||
| Q1 25 | -1.4% | 6.4% | ||
| Q4 24 | — | 13.0% | ||
| Q3 24 | -0.7% | 13.8% | ||
| Q2 24 | — | 8.0% | ||
| Q1 24 | -8.0% | 4.0% |
每股收益（稀释后）REAXRVTY
| Q4 25 | — | $0.86 | ||
| Q3 25 | $0.00 | $0.40 | ||
| Q2 25 | $0.01 | $0.46 | ||
| Q1 25 | $-0.02 | $0.35 | ||
| Q4 24 | — | $0.77 | ||
| Q3 24 | $-0.01 | $0.77 | ||
| Q2 24 | — | $0.45 | ||
| Q1 24 | $-0.09 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $38.7M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $53.6M | $7.3B |
| 总资产 | $145.2M | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资REAXRVTY
| Q4 25 | — | $919.9M | ||
| Q3 25 | $38.7M | $931.4M | ||
| Q2 25 | $49.7M | $991.8M | ||
| Q1 25 | $24.7M | $1.1B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | $22.6M | $1.2B | ||
| Q2 24 | — | $2.0B | ||
| Q1 24 | $20.1M | $1.7B |
股东权益REAXRVTY
| Q4 25 | — | $7.3B | ||
| Q3 25 | $53.6M | $7.4B | ||
| Q2 25 | $49.2M | $7.6B | ||
| Q1 25 | $32.8M | $7.6B | ||
| Q4 24 | — | $7.7B | ||
| Q3 24 | $29.8M | $7.9B | ||
| Q2 24 | — | $7.9B | ||
| Q1 24 | $25.6M | $7.8B |
总资产REAXRVTY
| Q4 25 | — | $12.2B | ||
| Q3 25 | $145.2M | $12.1B | ||
| Q2 25 | $149.4M | $12.4B | ||
| Q1 25 | $100.5M | $12.4B | ||
| Q4 24 | — | $12.4B | ||
| Q3 24 | $102.5M | $12.8B | ||
| Q2 24 | — | $13.4B | ||
| Q1 24 | — | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $8.8M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $8.4M | $161.8M |
| 自由现金流率自由现金流/营收 | 1.5% | 21.0% |
| 资本支出强度资本支出/营收 | 0.1% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $71.7M | $509.4M |
8季度趋势，按日历期对齐
经营现金流REAXRVTY
| Q4 25 | — | $182.0M | ||
| Q3 25 | $8.8M | $138.5M | ||
| Q2 25 | $41.0M | $134.3M | ||
| Q1 25 | $15.9M | $128.2M | ||
| Q4 24 | — | $174.2M | ||
| Q3 24 | $7.2M | $147.9M | ||
| Q2 24 | — | $158.6M | ||
| Q1 24 | $21.5M | $147.6M |
自由现金流REAXRVTY
| Q4 25 | — | $161.8M | ||
| Q3 25 | $8.4M | $120.0M | ||
| Q2 25 | $40.8M | $115.5M | ||
| Q1 25 | $15.7M | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | $6.8M | $125.6M | ||
| Q2 24 | — | $136.6M | ||
| Q1 24 | $21.4M | $129.7M |
自由现金流率REAXRVTY
| Q4 25 | — | 21.0% | ||
| Q3 25 | 1.5% | 17.2% | ||
| Q2 25 | 7.5% | 16.0% | ||
| Q1 25 | 4.4% | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | 1.8% | 18.4% | ||
| Q2 24 | — | 19.7% | ||
| Q1 24 | 10.7% | 20.0% |
资本支出强度REAXRVTY
| Q4 25 | — | 2.6% | ||
| Q3 25 | 0.1% | 2.6% | ||
| Q2 25 | 0.0% | 2.6% | ||
| Q1 25 | 0.1% | 2.4% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | 0.1% | 3.3% | ||
| Q2 24 | — | 3.2% | ||
| Q1 24 | 0.0% | 2.7% |
现金转化率REAXRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | 27.13× | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
REAX
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
